JP2025512995A - カンナビノイド受容体１アンタゴニスト／インバースアゴニスト及びその使用 - Google Patents

カンナビノイド受容体１アンタゴニスト／インバースアゴニスト及びその使用 Download PDF

Info

Publication number
JP2025512995A
JP2025512995A JP2024559421A JP2024559421A JP2025512995A JP 2025512995 A JP2025512995 A JP 2025512995A JP 2024559421 A JP2024559421 A JP 2024559421A JP 2024559421 A JP2024559421 A JP 2024559421A JP 2025512995 A JP2025512995 A JP 2025512995A
Authority
JP
Japan
Prior art keywords
compound
mmol
alkyl
pharma
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024559421A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025512995A5 (enExample
Inventor
モーニングスター，マーシャル
ジン，ズアン
デン，ホンフェン
Original Assignee
コーバス ファーマシューティカルズ インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コーバス ファーマシューティカルズ インコーポレーテッド filed Critical コーバス ファーマシューティカルズ インコーポレーテッド
Publication of JP2025512995A publication Critical patent/JP2025512995A/ja
Publication of JP2025512995A5 publication Critical patent/JP2025512995A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024559421A 2022-04-07 2023-04-07 カンナビノイド受容体１アンタゴニスト／インバースアゴニスト及びその使用 Pending JP2025512995A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263328611P 2022-04-07 2022-04-07
US63/328,611 2022-04-07
US202363439645P 2023-01-18 2023-01-18
US63/439,645 2023-01-18
PCT/US2023/017817 WO2023196556A1 (en) 2022-04-07 2023-04-07 Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof

Publications (2)

Publication Number Publication Date
JP2025512995A true JP2025512995A (ja) 2025-04-22
JP2025512995A5 JP2025512995A5 (enExample) 2026-04-14

Family

ID=88243528

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024559421A Pending JP2025512995A (ja) 2022-04-07 2023-04-07 カンナビノイド受容体１アンタゴニスト／インバースアゴニスト及びその使用

Country Status (12)

Country Link
US (1) US20250248973A1 (enExample)
EP (1) EP4504179A4 (enExample)
JP (1) JP2025512995A (enExample)
KR (1) KR20250008741A (enExample)
CN (1) CN119325378A (enExample)
AU (1) AU2023250955A1 (enExample)
CA (1) CA3255170A1 (enExample)
GB (1) GB2633943A (enExample)
IL (1) IL315945A (enExample)
MX (1) MX2024012263A (enExample)
WO (1) WO2023196556A1 (enExample)
ZA (1) ZA202407552B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121816344A (zh) * 2023-08-21 2026-04-07 杭州德睿智药科技有限公司 用于选择性调节大麻素cb1功能的新型杂环类化合物
WO2025103493A1 (zh) * 2023-11-16 2025-05-22 西藏海思科制药有限公司 一种大麻素受体1拮抗剂及其应用
WO2025185689A1 (zh) * 2024-03-08 2025-09-12 成都轻胜生物医药科技有限公司 吡唑衍生物及其用途
CN118580162A (zh) * 2024-05-27 2024-09-03 中国药科大学 一种酰肼类化合物及无金属策略促进酰肼类化合物制备的方法
US20260092038A1 (en) * 2024-09-27 2026-04-02 Corbus Pharmaceuticals, Inc. Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2003698A3 (cs) * 2001-03-22 2003-06-18 Solvay Pharmaceuticals B. V. 4,5-Dihydro-1H-pyrazolové deriváty mající CB1-antagonistickou účinnost
US7655685B2 (en) * 2007-11-02 2010-02-02 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
WO2012068529A2 (en) * 2010-11-18 2012-05-24 Jenrin Discovery Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes
KR20150113762A (ko) * 2014-03-31 2015-10-08 한미약품 주식회사 황 작용기를 포함하는 4,5-다이하이드로-1h-피라졸-3-카복스이미드아마이드 유도체, 이의 제조방법 및 이를 포함하는 약학 조성물
EP3109237A1 (en) * 2015-06-22 2016-12-28 AnaMar AB Novel 5-ht2 antagonists
WO2020236411A1 (en) * 2019-05-17 2020-11-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A scalable synthesis of dual-target inhibitor of cannabinoid-1 receptor and inducible nitric oxide synthase

Also Published As

Publication number Publication date
US20250248973A1 (en) 2025-08-07
GB2633943A (en) 2025-03-26
ZA202407552B (en) 2025-12-17
WO2023196556A1 (en) 2023-10-12
EP4504179A4 (en) 2026-01-07
AU2023250955A1 (en) 2024-10-17
IL315945A (en) 2024-11-01
KR20250008741A (ko) 2025-01-15
GB202416413D0 (en) 2024-12-25
CA3255170A1 (en) 2023-10-12
EP4504179A1 (en) 2025-02-12
CN119325378A (zh) 2025-01-17
MX2024012263A (es) 2025-01-09

Similar Documents

Publication Publication Date Title
US20250248973A1 (en) Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof
CN109863140B (zh) 3-氧代-2,6-二苯基-2,3-二氢哒嗪-4-甲酰胺
CN108738320B (zh) 用于治疗心血管疾病的cGMP调节剂
CN105008362B (zh) 作为詹纳斯相关激酶(jak)抑制剂的吡咯并[2,3‑d]嘧啶衍生物
CN109415321B (zh) 芳族磺酰胺衍生物
JP5837482B2 (ja) ピラゾールオキサジアゾール誘導体
TWI772309B (zh) 化合物及其於降低尿酸位準之用途(二)
PT1024138E (pt) Derivados de pirazole
CN104822680A (zh) 咪唑并吡啶化合物
CA3047002A1 (en) Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
TWI891227B (zh) 用於治療與apj受體活性相關的病狀的化合物及組成物
JP2020508996A (ja) リシルオキシダーゼのハロアリルアミンピラゾール誘導体阻害剤およびその使用
SG11202108792WA (en) Substituted bicyclic compounds as farnesoid x receptor modulators
CN115413279A (zh) P2x3调节剂
CN110121341A (zh) 可用作二酰基甘油酯o-酰基转移酶2的抑制剂的吲唑衍生物
AU2017290705A1 (en) Compounds and compositions for the treatment of cancer
KR20210130753A (ko) Hbv 감염 또는 hbv-유발성 질환의 치료에 유용한 아미드 유도체
CN109641909B (zh) 雷帕霉素信号通路抑制剂的机理靶标及其治疗应用
CN105916506A (zh) 作为tam家族激酶抑制剂的喹唑啉衍生物
WO2015162452A1 (en) Substituted pyrazole compounds as cb1 receptor antagonists and uses thereof
HK40122921A (en) Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof
WO2026102129A1 (en) Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof
CN114846004A (zh) 新型抗疟药
WO2026072914A1 (en) Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof
HK40130017A (en) Carbonic anhydrase enzyme inhibitors and methods of use thereof

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20250227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260406

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260406